戻る Agenda
Patient-Centricity: How do We Measure Progress in Involving Patients in Drug Development and Drug Safety?
Session Chair(s)
Mariette Boerstoel-Streefland, MD, MBA, MS
Senior Vice President, Patient Safety Officer
Bristol Myers Squibb, United States
This session will highlight progress to date in identifying metrics to assess patient involvement in drug development and drug safety, and the current challenges to, and benefits of, achieving a more patient-centric culture within the pharmaceutical industry. Perspectives on this topic will be provided by representatives from IMI-PARADIGM, industry, the patient advocacy sector, and the US FDA. Join the DIA Patient Engagement Community for a follow up round table discussion (session #216 L-RT) on Tuesday, June 16, 10:45AM - 11:30AM.
Learning Objective : Discuss how to use a framework to guide selection of appropriate patient-centricity metrics for use within a pharmaceutical company; Describe the types of metrics that have been developed to date to measure patient involvement in drug development, including drug safety; Identify key challenges to implementing patient-centricity metrics within a pharmaceutical company and identify specific strategies to overcome those barriers.
Speaker(s)
FDA Update
Robyn Bent, BSN, MS, RN
FDA, United States
Director, Patient Focused Drug Development, OCD, CDER
Measuring Patient Engagement Progress: Part of a Comprehensive Change Leadership Plan
Katherine Capperella
Johnson & Johnson, United States
VP, Global Patient Engagement Leader
Patient-Centricity: How do We Measure Progress in Involving Patients in Drug Development and Drug Safety? - Policy Update
Elisabeth Oehrlein, PHD, MS
National Health Council (NHC), United States
Senior Director, Research and Programs
What Frameworks and Metrics Exist for Measuring Patient-Centricity in Drug Development and Drug Safety
Tjerk Jan Schuitmaker, PHD, MSC
Athena Institute of the Vrije University of Amsterdam , Netherlands
IMI-PARADIGM; Assistant Professor